Podcast debates FDA’s handling of Duchenne drugs and upcoming executive changes
read at STAT ↗Neutral
Allison DeAngelis, Adam Feuerstein and Elaine Chen host this week’s Readout Loud podcast, a STAT series that examines biotech trends and business moves.
The trio questions whether the FDA is applying consistent standards to therapies for Duchenne muscular dystrophy, highlighting recent data disputes that have surfaced in the field.
They also explore how a wave of new drug executives may reshape company strategies and note a personal anecdote about Adam speaking with a recruiter.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “Capricor’s data clash and a fugitive in the C-suite”
read at STAT ↗588 words · retrieved Jul 30
comments(0)
5-min edit window · permanent after that